These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19421773)

  • 21. DNA flow cytometry, clinical and morphological parameters as prognostic factors for advanced malignant and borderline ovarian tumors.
    Kühn W; Kaufmann M; Feichter GE; Rummel HH; Schmid H; Heberling D
    Gynecol Oncol; 1989 Jun; 33(3):360-7. PubMed ID: 2722063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA ploidy analysis of borderline epithelial ovarian tumours.
    Lodhi S; Najam S; Pervez S
    J Pak Med Assoc; 2000 Oct; 50(10):349-51. PubMed ID: 11109755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
    Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
    Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serous borderline tumor of the paratestis: a report of seven cases.
    McClure RF; Keeney GL; Sebo TJ; Cheville JC
    Am J Surg Pathol; 2001 Mar; 25(3):373-8. PubMed ID: 11224608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma.
    Lassus H; Staff S; Leminen A; Isola J; Butzow R
    Gynecol Oncol; 2011 Jan; 120(1):11-7. PubMed ID: 20937525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of p16INK4A expression in low-grade ovarian serous carcinomas.
    Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J
    Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A quantitative study on nuclear DNA content and morphological parameters in ovarian cystadenocarcinoma].
    Liu C; Zhao Y; Sun X
    Zhonghua Fu Chan Ke Za Zhi; 1995 Dec; 30(12):738-40. PubMed ID: 8728920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genomic imbalances in ovarian borderline serous and mucinous tumors.
    Hu J; Khanna V; Jones MM; Surti U
    Cancer Genet Cytogenet; 2002 Nov; 139(1):18-23. PubMed ID: 12547152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnostic difficulties in serous "borderline" tumors of the ovary].
    Vereczkey I; Tóth E; Orosz Z
    Magy Onkol; 2009 Mar; 53(1):23-31. PubMed ID: 19318323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Morphologic and morphometric features of low grade serous tumours of the ovary.
    Gurley AM; Hidvegi DF; Cajulis RS; Bacus S
    Diagn Cytopathol; 1994; 11(3):220-5. PubMed ID: 7867463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary.
    Kigawa J; Minagawa Y; Ishihara H; Kanamori Y; Terakawa N
    Cancer; 1993 Aug; 72(3):804-8. PubMed ID: 8334634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pattern of HER-2 Gene Amplification and Protein Expression in Benign, Borderline, and Malignant Ovarian Serous and Mucinous Neoplasms.
    Mohammed RAA; Makboul R; Elsers DAH; Elsaba TMAM; Thalab AMAB; Shaaban OM
    Int J Gynecol Pathol; 2017 Jan; 36(1):50-57. PubMed ID: 27309616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the landscape of ovarian serous borderline tumors.
    Messini I; Doulgeraki T; Chrysanthakis D; Yiannou P; Gavresea T; Papadimitriou C; Panoskaltsis T; Voulgaris Z; Vlachos A; Pavlakis K
    Int J Gynecol Cancer; 2019 Mar; 29(3):572-578. PubMed ID: 30659030
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation analysis of papillary tubal hyperplasia associated with ovarian atypical proliferative serous tumor and low-grade serous carcinoma.
    Huang WC; Tsai CC; Wei MC; Kuo KT
    Am J Obstet Gynecol; 2013 Aug; 209(2):e6-8. PubMed ID: 23711666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
    Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
    Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Borderline ovarian tumors.
    Baak JP; van Diest PJ
    Am J Surg Pathol; 1998 Jul; 22(7):904-7. PubMed ID: 9669355
    [No Abstract]   [Full Text] [Related]  

  • 38. Concurrent endometrial intraepithelial carcinoma (EIC) and serous ovarian cancer: can EIC be seen as the precursor lesion?
    Roelofsen T; van Kempen LC; van der Laak JA; van Ham MA; Bulten J; Massuger LF
    Int J Gynecol Cancer; 2012 Mar; 22(3):457-64. PubMed ID: 22249577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of nuclear morphometry and DNA ploidy status for detection of malignant and premalignant oral lesions: quantitative cytologic assessment and review of methods for cytomorphometric measurements.
    Pektas ZO; Keskin A; Günhan O; Karslioğlu Y
    J Oral Maxillofac Surg; 2006 Apr; 64(4):628-35. PubMed ID: 16546642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histopathological assessment of paraffin-embedded specimens.
    Scott IS; Heath TM; Morris LS; Rushbrook SM; Bird K; Vowler SL; Arends MJ; Coleman N
    Br J Cancer; 2004 Apr; 90(8):1583-90. PubMed ID: 15083189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.